Skip to main content
. 2021 Jun 17;13:4767–4776. doi: 10.2147/CMAR.S308833

Table 2.

Efficacy and Safety Comparison Between EBS and PTBD in Patients with Bismuth Types III–IV

EBS (n=97) PTBD (n=48) p
*Clinical success (%, ratio) 52.6% (50/95) 67.4% (31/46) 0.097
TBIL decrease (µmol/L) 36.70 66.90 0.006
Complication (%, ratio) 39.2%(38/97) 39.6% (19/48) 0.962
Cholangitis (%, ratio) 27.8% (27/97) 29.2% (14/48) 0.867
Hemorrhage (%, ratio) 3.1% (3/97) 2.1% (1/48) 1.000

Notes: *Postprocedure TBIL was missing in 2 cases in each group.